UNCY

Over the past six months, Unicycive Therapeutics' stock price has fluctuated. The stock saw a +3.62% increase on November 25, 2025, and a -2.31% change on December 29, 2025. On January 29, 2026, the FDA accepted the Oxylanthanum Carbonate (OLC) New Drug Application (NDA) resubmission, followed by a -4.99% change in stock price. The company participated in a fireside chat at Guggenheim's Emerging Outlook: Biotech Summit on February 4, 2026, with the stock decreasing by -5.92%. On March 30, 2026, the company announced its full-year 2025 financial results and provided a business update, leading to a -4.38% change in stock price. A director, Gaurav Aggarwal, stepped down from the board on April 6, 2026. Unicycive Therapeutics presented at the 25th Annual Needham Virtual Healthcare Conference on April 9, 2026, and the stock increased by +3.10%. An announcement was made on May 1, 2026, regarding the Annual General Meeting scheduled for June 19, 2026. The stock's 52-week range has been between $3.71 and $11.00.